NVO240628C130000
- 12.74
- -1.20-8.61%
Novo-Nordisk A/S Newsroom
The Top Country With Most Scientists per Capita in the World
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
Novo Nordisk Options Trading: A Deep Dive Into Market Sentiment
Deep-pocketed investors have adopted a bullish approach towards Novo Nordisk (NYSE:NVO), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled
Novo Nordisk Fully Valued Amid Limited Longer-Term Visibility -- Market Talk
1201 GMT - Novo Nordisk trades near all-time highs, with the stock priced for a sustainable GLP-1 franchise beyond the patent expiration of its blockbuster semaglutide drug, UBS analyst Jo Walton writ
"Muscle gain and fat loss" becomes a new trend in the tens of billions of weight loss market, attracting attention with the cooperation between Kalbe Pharma-B (02105) and Novo Nordisk on muscle gain and fat loss research.
With the mutual efforts with Novo-Nordisk, Laike Pharmaceutical is expected to become a frontrunner in the global weight loss market worth hundreds of billions, and achieve a leap in its own valuation in the future.
Top Gap Ups and Downs on Thursday: MU, SONY, ZTS and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Novo Nordisk (NVO) Rises Higher Than Market: Key Facts
Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
On Thursday, 2seventy Bio Inc. (NASDAQ:TSVT) completed the asset purchase agreement with Novo Nordisk A/S (NYSE:NVO).Under the terms, Novo Nordisk has acquired the Hemophilia A program and rights to 2
Novo Nordisk To Restrict Initial Wegovy Sales In China Amid High Demand
Novo Nordisk A/S (NYSE:NVO) plans to limit initial sales of its obesity treatment Wegovy in China as the Danish drugmaker faces the challenge of balancing demand while ensuring global supply.China's N
Novo Nordisk's (NVO) Hypertension Drug Study Fails to Meet Goal
Him & Hers Down 6% Following Report on 'Shady Supplier' for Weight Loss Drug
Novo Nordisk Shows Its Vulnerable Side After Drug Trial Failure -- Market Talk
1319 GMT - Novo Nordisk will recognize an impairment loss of around DKK5.7 billion in 2Q after a blood pressure drug trial failed to meet its primary endpoint, a result that shows the Danish pharma gi
Market Chatter: Novo Nordisk to Limit Launch of Wegovy in China, Executive Says
Novo Nordisk (NVO) intends to launch Wegovy on a limited basis in China soon, Bloomberg reported Thursday, citing the company's chief of international operations, Maziar Mike Doustdar. The Danish drug
2seventy bio (TSVT.US) rose nearly 4% in pre-market trading! Its type A hemophilia project was acquired by Novo Nordisk A/S (NVO.US).
Zhītōng Cáijīng APP learned that 2seventy bio (TSVT.US) has announced the completion of an assets purchase agreement. According to the agreement, Novo Nordisk (NVO.US) will acquire 2seventy bio's type A hemophilia project. In addition, Novo Nordisk will also acquire the rights to 2seventy bio's in-body gene editing technology. This technology is used for autologous or allogeneic cell therapy of immune cells for the treatment of autoimmune diseases. 2seventy bio also stated that the team currently involved in this project will join Novo Nordisk and...
Novo Nordisk Buys 2seventy Bio's Hemophilia A Program
Zhejiang Int'l Group (000411.SZ) has business collaborations with large pharmaceutical companies including Eli Lilly and Co, Novo-Nordisk A/S.
Zhejiang Int'l Group (000411.SZ) stated on the investor interaction platform on June 27th that the company is a pharmaceutical distribution enterprise mainly engaged in the wholesale and retail business of pharmaceuticals and medical instruments, and has business cooperation with large pharmaceutical enterprises including Eli Lilly and Co and Novo-Nordisk A/S. At present, the company operates tens of thousands of varieties and specifications of pharmaceutical products, including hypoglycemic products, but the sales of specific single variety and specification account for a small proportion of the company's overall sales. The company will continue to pay attention to newly launched drugs and actively carry out relevant introduction work.
Ben & Jerry's Co-Founders Not Worried About Ozempic's Impact On Ice Cream Business: Here's Why
Ben Cohen and Jerry Greenfield, the co-founders of Ben & Jerry's, are not worried about the impact of weight-loss drugs on their ice cream business, despite the impending spin-off of their parent comp
Novo Holdings and DLG Group Join Forces to Advance Sustainable Crop Production
COPEHAGEN, Denmark, June 27, 2024 /PRNewswire/ -- Novo Holdings and DLG Group today announced a strategic partnership to advance sustainable agriculture and food systems.
Novo Nordisk's oral dual agonist approved for clinical use in China.
On June 26th, China's National Medical Products Administration's Drug Evaluation Center website announced that the first class new drug amycretin tablet from Novo Nordisk (NVO.US) has been approved for clinical use, intended for reducing the weight of overweight or obese adult patients. Publicly available data shows that this is a new generation of weight loss therapy, developed by Novo Nordisk, an oral GLP-1 and insulin receptor long-acting agonist. In a small Phase 1 clinical study previously published by Novo Nordisk, patients receiving the treatment with the product experienced a weight loss of 13.1% after 12 weeks (vs. 1.1% in the placebo group), demonstrating rapid weight loss.
Bernie Sanders: 'Ozempic Will Likely Become One Of The Best-Selling Pharmaceutical Products In History' — Americans Shouldn't Pay 10-15X More
In a recent tweet, Bernie Sanders (I-Vt.) criticized the pricing of a popular diabetes drug, Ozempic, and its manufacturer, Novo Nordisk A/S (NYSE:NVO).What Happened: Sanders took to X, formerly Twitt